ERBB2 and breast carcinoma: Table 2 presents the annual average direct costs per person among patients with HER2-positive breast cancer treated with trastuzumab compared to matched controls free of breast cancer among the total study population, the population with metastatic or recurrence of breast cancer and the population without metastatic or recurrence of breast cancer.